Document is current

Article History

Received: 1 October 2019

Accepted: 18 February 2020

First Online: 10 March 2020

Ethics approval and consent to participate

: This study has been conducted according to the principles of the declaration of Helsinki 2008. Ethical approval has been granted from Institutional Review Boards at Fox Chase Cancer Center, MD Anderson Cancer Center and H. Lee Moffitt Cancer Center (University of South Florida). All patients signed an informed consent for participating in this trial, including the option of publication of the data.

: Not applicable

: The data are available for all study authors. The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

: N.V.: Research funding from Merck, Bayer. A.D.: Consulting fee from Novartis, Ipsen, Voluntis, Abbvie, Crinetics, Hutchison Pharma and Research funding from Novartis, Eisai, Ipsen, Hutchison Pharma. D.H.: Consulting fee from Lexicon, Ipsen, Advanced Accelarator Applications; Research funding from Genentech, Tarveda, ThermoFisher Scientific. C.D.: Personal fees from Exelixis Astellas, BeiGene, Bayer, Bristol Myer Squibb, Merck, Eli Lilly & Co, EMD Serono; Research funding from Merrimack Pharmaceuticals, Advaxis, Astra Zeneca, Eli Lilly & Co, Roche/Genentech, Amgen, Sanofi Aventis, BeiGene, Lycera, Macrogenics, Agios Pharmaceuticals, Zymeworks, outside the submitted work. M.J.H.: Research funding from Merck, Astra Zeneca. E.D.: Honararia from Pfizer, Boston Medical; Consulting fee from ARMO Biosciences; Research funding from Pfizer, Bayer, Boston Biomedical, Merck, Medimmune, GSK and Eli Lilly Co. J.S.: Consultant fee from Novartis, Speakers bureau for Lexicon and Ipsen.

: The study was supported by research grant MISP# 53956 from Merck, and NCI Comprehensive Cancer Center Support Grant CA06927.